{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:54:38Z","timestamp":1783036478758,"version":"3.54.6"},"reference-count":149,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hairy cell leukemia (HCL) is a chronic B-cell lymphoproliferative disorder that is characterized by pancytopenia, splenomegaly, and hepatomegaly, resulting from the organ-specific infiltration of \u201chairy\u201d leukemic cells. Despite tremendous therapeutic advances with purine analogs and interferon, approximately half of patients with HCL relapse after initial treatment. The discovery of valine-to-glutamic acid mutation at amino acid 600 on B-rapidly accelerated fibrosarcoma [BRAF(V600E)] in HCL, revealed an aberrant MAPK signaling pathway that drives the proliferation and survival of HCL B cells, provides a promising and effective target for treating patients who have developed resistance to myelotoxic and immune-suppressive drugs. More recently, 2 BRAF(V600E)-based HCL mouse models have been developed that could be extremely useful both for functional studies and for testing the activity of new drugs. This review aims to summarize current understanding of key pathogenic mechanisms underlying HCL development and discusses major hurdles that need to be overcome in the context of other BRAF-mutated malignancies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017165","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:04:28Z","timestamp":1764173068000},"page":"1012-1022","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Hairy cell leukemia: a chronic B-cell lymphoma with unique clinicopathological features and unresolved molecular mechanisms"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3249-0129","authenticated-orcid":false,"given":"Ge","family":"Zhang","sequence":"first","affiliation":[{"name":"1Laboratory of Molecular Mechanism and Targeted Therapy, Division of Cellular and Molecular Research, National Cancer Center Singapore, Singapore General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1615-0030","authenticated-orcid":false,"given":"Jiancheng","family":"Hu","sequence":"additional","affiliation":[{"name":"1Laboratory of Molecular Mechanism and Targeted Therapy, Division of Cellular and Molecular Research, National Cancer Center Singapore, Singapore General Hospital, Singapore"},{"name":"2Cancer and Stem Cell Biology Program, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"issue":"7","key":"2026022411375626400_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.V13.7.609.609","article-title":"Leukemic reticuloendotheliosis","volume":"13","author":"Bouroncle","year":"1958","journal-title":"Blood"},{"issue":"19","key":"2026022411375626400_bib2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2026022411375626400_bib3","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/ajh.26390","article-title":"Hairy cell leukemia 2022: update on diagnosis, risk-stratification, and treatment","volume":"97","author":"Troussard","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"2026022411375626400_bib4","doi-asserted-by":"crossref","first-page":"E116","DOI":"10.1002\/ajh.26881","article-title":"Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysis","volume":"98","author":"Epperla","year":"2023","journal-title":"Am J Hematol"},{"issue":"suppl 16","key":"2026022411375626400_bib5","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1200\/JCO.2022.40.16_suppl.7577","article-title":"Impact of sex on outcomes in patients with hairy cell leukemia (HCL): an HCL patient data registry (PDR) analysis","volume":"40","author":"Epperla","year":"2022","journal-title":"Am Soc Clin Oncol"},{"issue":"1","key":"2026022411375626400_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N Engl J Med"},{"issue":"1","key":"2026022411375626400_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/blood-2009-06-195370","article-title":"How I treat hairy cell leukemia","volume":"115","author":"Grever","year":"2010","journal-title":"Blood"},{"issue":"4","key":"2026022411375626400_bib8","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-term follow-up after purine analogue therapy in hairy cell leukaemia","volume":"28","author":"Else","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"issue":"6","key":"2026022411375626400_bib9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"issue":"4","key":"2026022411375626400_bib10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/17474086.2021.1908121","article-title":"Diagnostic and therapeutic challenges in hairy cell leukemia-variant: where are we in 2021?","volume":"14","author":"Matutes","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"2026022411375626400_bib11","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2007-07-098848","article-title":"Splenic red pulp lymphoma with numerous basophilic villous lymphocytes: a distinct clinicopathologic and molecular entity?","volume":"111","author":"Traverse-Glehen","year":"2008","journal-title":"Blood"},{"issue":"24","key":"2026022411375626400_bib12","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N Engl J Med"},{"issue":"1","key":"2026022411375626400_bib13","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1182\/blood-2011-08-371179","article-title":"Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation","volume":"119","author":"Tiacci","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2026022411375626400_bib14","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2011-08-368209","article-title":"The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms","volume":"119","author":"Arcaini","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2026022411375626400_bib15","first-page":"253","article-title":"BRAF mutation in hairy cell leukemia","volume":"8","author":"Ahmadzadeh","year":"2014","journal-title":"Oncol Rev"},{"issue":"18","key":"2026022411375626400_bib16","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"2026022411375626400_bib17","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood.2021013658","article-title":"Dabrafenib plus trametinib in patients with relapsed\/refractory BRAF V600E mutation\u2013positive hairy cell leukemia","volume":"141","author":"Kreitman","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2026022411375626400_bib18","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa2031298","article-title":"Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia","volume":"384","author":"Tiacci","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2026022411375626400_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-023-01817-8","article-title":"BRAF (V600E) mutation together with loss of Trp53 or pTEN drives the origination of hairy cell leukemia from B-lymphocytes","volume":"22","author":"Yap","year":"2023","journal-title":"Mol Cancer"},{"key":"2026022411375626400_bib20","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nrc1888","article-title":"Evolving concepts in the pathogenesis of hairy-cell leukaemia","volume":"6","author":"Tiacci","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"suppl 2","key":"2026022411375626400_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3109\/10428194.2011.565095","article-title":"Surface topography of hairy cell leukemia cells compared to other leukemias as seen by scanning electron microscopy","volume":"52","author":"Polliack","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2026022411375626400_bib22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0145-2126(00)00079-5","article-title":"Aberrant expression and localization of the cytoskeleton-binding pp52 (LSP1) protein in hairy cell leukemia","volume":"25","author":"Miyoshi","year":"2001","journal-title":"Leuk Res"},{"issue":"3","key":"2026022411375626400_bib23","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/BF02983784","article-title":"Constitutively activated Rho guanosine triphosphatases regulate the growth and morphology of hairy cell leukemia cells","volume":"77","author":"Zhang","year":"2003","journal-title":"Int J Hematol"},{"issue":"2","key":"2026022411375626400_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s11864-014-0285-5","article-title":"Update on the biology and treatment options for hairy cell leukemia","volume":"15","author":"Jain","year":"2014","journal-title":"Curr Treat Options Oncol"},{"issue":"1","key":"2026022411375626400_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1365-2141.1998.00653.x","article-title":"VH gene expression in hairy cell leukaemia","volume":"101","author":"Maloum","year":"1998","journal-title":"Br J Haematol"},{"issue":"10","key":"2026022411375626400_bib26","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1182\/blood-2004-03-0950","article-title":"Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch","volume":"104","author":"Forconi","year":"2004","journal-title":"Blood"},{"issue":"4","key":"2026022411375626400_bib27","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood.V98.4.1174","article-title":"Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing","volume":"98","author":"Forconi","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2026022411375626400_bib28","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood-2004-01-0181","article-title":"Comparative expressed sequence hybridization studies of hairy cell leukemia show uniform expression profile and imprint of spleen signature","volume":"104","author":"Vanhentenrijk","year":"2004","journal-title":"Blood"},{"issue":"10","key":"2026022411375626400_bib29","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.leu.2403503","article-title":"VH gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin","volume":"18","author":"Vanhentenrijk","year":"2004","journal-title":"Leukemia"},{"issue":"1","key":"2026022411375626400_bib30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1084\/jem.20031175","article-title":"Gene expression profiling of hairy cell leukemia reveals a phenotype related to memory B cells with altered expression of chemokine and adhesion receptors","volume":"199","author":"Basso","year":"2004","journal-title":"J Exp Med"},{"key":"2026022411375626400_bib31","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/bloodadvances.2018024059","article-title":"Genome-wide promoter methylation of hairy cell leukemia","volume":"3","author":"Arribas","year":"2019","journal-title":"Blood Adv"},{"issue":"12","key":"2026022411375626400_bib32","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/10428190410001723449","article-title":"Chemokine receptor expression in B-cell lymphoproliferative disorders","volume":"45","author":"Wong","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2026022411375626400_bib33","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1349-7006.2009.01177.x","article-title":"Cancer stem cells and their niche","volume":"100","author":"Iwasaki","year":"2009","journal-title":"Cancer Sci"},{"issue":"10","key":"2026022411375626400_bib34","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1182\/blood.V88.10.3945.bloodjournal88103945","article-title":"Endothelial interactions of hairy cells: the importance of alpha 4 beta 1 in the unusual tissue distribution of the disorder","volume":"88","author":"Vincent","year":"1996","journal-title":"Blood"},{"issue":"2","key":"2026022411375626400_bib35","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1182\/blood.V100.2.647","article-title":"Response of hairy cells to IFN-\u03b1 involves induction of apoptosis through autocrine TNF-\u03b1 and protection by adhesion","volume":"100","author":"Baker","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2026022411375626400_bib36","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1182\/blood.V84.3.873.873","article-title":"Hairy cell interactions with extracellular matrix: expression of specific integrin receptors and their role in the cell's response to specific adhesive proteins","volume":"84","author":"Burthem","year":"1994","journal-title":"Blood"},{"issue":"5","key":"2026022411375626400_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/ajcp\/67.5.415","article-title":"Splenic pseudosinuses and hepatic angiomatous lesions: distinctive features of hairy cell leukemia","volume":"67","author":"Nanba","year":"1977","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2026022411375626400_bib38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0344-0338(87)80110-3","article-title":"Altered basement membrane structure of the spleen in hairy cell leukaemia: demonstration of laminin in hairy cells","volume":"182","author":"Karttunen","year":"1987","journal-title":"Pathol Res Pract"},{"issue":"9","key":"2026022411375626400_bib39","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood.V96.9.3161","article-title":"Involvement of CD44-hyaluronan interaction in malignant cell homing and fibronectin synthesis in hairy cell leukemia","volume":"96","author":"Aziz","year":"2000","journal-title":"Blood"},{"issue":"5","key":"2026022411375626400_bib40","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1172\/JCI19540","article-title":"TGF-\u03b21 induces bone marrow reticulin fibrosis in hairy cell leukemia","volume":"113","author":"Shehata","year":"2004","journal-title":"J Clin Invest"},{"issue":"9","key":"2026022411375626400_bib41","doi-asserted-by":"crossref","first-page":"3134","DOI":"10.1182\/blood.V84.9.3134.3134","article-title":"Proliferation and cytogenetic analysis of hairy cell leukemia upon stimulation via the CD40 antigen","volume":"84","author":"Kluin-Nelemans","year":"1994","journal-title":"Blood"},{"issue":"8","key":"2026022411375626400_bib42","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2015-04-643361","article-title":"Recurrent CDKN1B (p27) mutations in hairy cell leukemia","volume":"126","author":"Dietrich","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2026022411375626400_bib43","first-page":"33","article-title":"Correlation of serum levels of interleukin-1 family members with disease activity and response to treatment in hairy cell leukemia","volume":"9","author":"Barak","year":"1998","journal-title":"Eur Cytokine Netw"},{"issue":"12","key":"2026022411375626400_bib44","first-page":"788","article-title":"Origin of the soluble interleukin-2 receptor in the serum of patients with hairy cell leukemia","volume":"2","author":"Semenzato","year":"1988","journal-title":"Leukemia"},{"issue":"4","key":"2026022411375626400_bib45","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1309\/AJCPEBK31VQQNDDR","article-title":"CD200 flow cytometric assessment and semiquantitative immunohistochemical staining distinguishes hairy cell leukemia from hairy cell leukemia-variant and other B-cell lymphoproliferative disorders","volume":"140","author":"Pillai","year":"2013","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2026022411375626400_bib46","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1309\/AJCP2F2DOXOTXHZA","article-title":"The diagnostic value of CD1d expression in a large cohort of patients with B-cell chronic lymphoproliferative disorders","volume":"136","author":"Kotsianidis","year":"2011","journal-title":"Am J Clin Pathol"},{"issue":"9424","key":"2026022411375626400_bib47","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(04)16356-3","article-title":"Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1)","volume":"363","author":"Falini","year":"2004","journal-title":"The Lancet"},{"issue":"5","key":"2026022411375626400_bib48","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"issue":"15","key":"2026022411375626400_bib49","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood-2016-07-418434","article-title":"BRAF V600E mutation in hairy cell leukemia: from bench to bedside","volume":"128","author":"Falini","year":"2016","journal-title":"Blood"},{"issue":"14","key":"2026022411375626400_bib50","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2017-01-765107","article-title":"Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations","volume":"130","author":"Durham","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2026022411375626400_bib51","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/bjh.12735","article-title":"Alternative BRAF mutations in BRAF V 600 E-negative hairy cell leukaemias","volume":"165","author":"Tschernitz","year":"2014","journal-title":"Br J Haematol"},{"issue":"17","key":"2026022411375626400_bib52","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/jcmm.17890","article-title":"Hairy cell leukaemia with unusual BRAF mutations","volume":"27","author":"Maitre","year":"2023","journal-title":"J Cell Mol Med"},{"issue":"11","key":"2026022411375626400_bib53","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2169\/internalmedicine.54.2944","article-title":"Hairy cell leukemia with systemic lymphadenopathy: detection of BRAF mutations in both lymph node and peripheral blood specimens","volume":"54","author":"Okada","year":"2015","journal-title":"Intern Med"},{"issue":"6","key":"2026022411375626400_bib54","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/bjh.12429","article-title":"BRAF V600E mutation-specific antibody, a sensitive diagnostic marker revealing minimal residual disease in hairy cell leukaemia","volume":"162","author":"Akarca","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"2026022411375626400_bib55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2011","journal-title":"Nat Genet"},{"issue":"48","key":"2026022411375626400_bib56","doi-asserted-by":"crossref","first-page":"28866","DOI":"10.18632\/oncotarget.25601","article-title":"New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes","volume":"9","author":"Maitre","year":"2018","journal-title":"Oncotarget"},{"issue":"9","key":"2026022411375626400_bib57","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1200\/JCO.2016.71.1556","article-title":"Genomics of hairy cell leukemia","volume":"35","author":"Tiacci","year":"2017","journal-title":"J Clin Oncol"},{"issue":"14","key":"2026022411375626400_bib58","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1182\/blood-2011-09-379339","article-title":"Both variant and IGHV4-34\u2013expressing hairy cell leukemia lack the BRAF V600E mutation","volume":"119","author":"Xi","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2026022411375626400_bib59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/ng.2828","article-title":"High prevalence of MAP2K1 mutations in variant and IGHV4-34\u2013expressing hairy-cell leukemias","volume":"46","author":"Waterfall","year":"2014","journal-title":"Nat Genet"},{"key":"2026022411375626400_bib60","doi-asserted-by":"crossref","first-page":"1068981","DOI":"10.3389\/fonc.2022.1068981","article-title":"Novel targeted treatments in hairy cell leukemia and other hairy cell-like disorders","volume":"12","author":"Maitre","year":"2022","journal-title":"Front Oncol"},{"issue":"22","key":"2026022411375626400_bib61","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-13-1848","article-title":"Bendamustine and rituximab in relapsed and refractory hairy cell leukemia","volume":"19","author":"Burotto","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2026022411375626400_bib62","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2014-10-603100","article-title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity","volume":"125","author":"Pettirossi","year":"2015","journal-title":"Blood"},{"issue":"238","key":"2026022411375626400_bib63","doi-asserted-by":"crossref","first-page":"238ra271","DOI":"10.1126\/scitranslmed.3008004","article-title":"Hematopoietic stem cell origin of BRAF V600E mutations in hairy cell leukemia","volume":"6","author":"Chung","year":"2014","journal-title":"Sci Transl Med"},{"issue":"19","key":"2026022411375626400_bib64","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1182\/bloodadvances.2020001926","article-title":"BRAFV600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell\u2013like histiocytosis in immune-deficient mice","volume":"4","author":"Rafiei","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2026022411375626400_bib65","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2141.2000.02210.x","article-title":"Low expression of p27 and low proliferation index do not correlate in hairy cell leukaemia","volume":"111","author":"Chilosi","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"2026022411375626400_bib66","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.semcancer.2011.10.005","article-title":"Oncogene-and tumor suppressor gene-mediated suppression of cellular senescence","volume":"21","author":"Larsson","year":"2011","journal-title":"Semin Cancer Biol"},{"issue":"15","key":"2026022411375626400_bib67","doi-asserted-by":"crossref","first-page":"3699","DOI":"10.1038\/sj.emboj.7601790","article-title":"Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation","volume":"26","author":"Le Sage","year":"2007","journal-title":"The EMBO J"},{"key":"2026022411375626400_bib68","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1073\/pnas.1013168108","article-title":"Kr\u00fcppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression","volume":"108","author":"Hart","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026022411375626400_bib69","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/leu.2014.294","article-title":"The Kr\u00fcppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma","volume":"29","author":"Piva","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"2026022411375626400_bib70","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0145-2126(99)00127-7","article-title":"p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant","volume":"23","author":"Vallianatou","year":"1999","journal-title":"Leuk Res"},{"issue":"4","key":"2026022411375626400_bib71","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/sj.leu.2401721","article-title":"p53 mutations in hairy cell leukemia","volume":"14","author":"K\u00f6nig","year":"2000","journal-title":"Leukemia"},{"issue":"21","key":"2026022411375626400_bib72","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2026022411375626400_bib73","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1038\/leu.2012.149","article-title":"A microRNA signature specific for hairy cell leukemia and associated with modulation of the MAPK\u2013JNK pathways","volume":"26","author":"Kitagawa","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"2026022411375626400_bib74","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1365-2141.1995.tb05429.x","article-title":"Increased expression of the PRAD-1\/CCND1 gene in hairy cell leukaemia","volume":"91","author":"Bosch","year":"1995","journal-title":"Br J Haematol"},{"issue":"3","key":"2026022411375626400_bib75","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/oxfordjournals.annonc.a010568","article-title":"Involvement of the CCND1 gene in hairy cell leukemia","volume":"7","author":"De Boer","year":"1996","journal-title":"Ann Oncol"},{"issue":"1","key":"2026022411375626400_bib76","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-020-00949-4","article-title":"The MAPK and AMPK signalings: interplay and implication in targeted cancer therapy","volume":"13","author":"Yuan","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"6892","key":"2026022411375626400_bib77","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"6","key":"2026022411375626400_bib78","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S0092-8674(04)00215-6","article-title":"Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF","volume":"116","author":"Wan","year":"2004","journal-title":"Cell"},{"issue":"4","key":"2026022411375626400_bib79","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3324\/haematol.2012.078071","article-title":"Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia","volume":"98","author":"Tiacci","year":"2013","journal-title":"haematologica"},{"issue":"23","key":"2026022411375626400_bib80","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF inhibition in hairy cell leukemia with low-dose vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"issue":"554","key":"2026022411375626400_bib81","doi-asserted-by":"crossref","first-page":"eaar6795","DOI":"10.1126\/scisignal.aar6795","article-title":"Activating mutations in MEK1 enhance homodimerization and promote tumorigenesis","volume":"11","author":"Yuan","year":"2018","journal-title":"Sci Signal"},{"issue":"5","key":"2026022411375626400_bib82","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.7150\/thno.103958","article-title":"Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37\/Hsp90 chaperone and the 14-3-3 scaffold","volume":"15","author":"Wan","year":"2025","journal-title":"Theranostics"},{"issue":"3","key":"2026022411375626400_bib83","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/ejh.12427","article-title":"B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells","volume":"94","author":"Seda","year":"2015","journal-title":"Eur J Haematol"},{"issue":"4","key":"2026022411375626400_bib84","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrc3702","article-title":"Targeting Bruton's tyrosine kinase in B cell malignancies","volume":"14","author":"Hendriks","year":"2014","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2026022411375626400_bib85","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/bjh.12867","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach","volume":"166","author":"Sivina","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"2026022411375626400_bib86","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2012.163","article-title":"Hairy cell leukemia cell lines expressing annexin A1 and displaying B-cell receptor signals characteristic of primary tumor cells lack the signature BRAF mutation to reveal unrepresentative origins","volume":"27","author":"Weston-Bell","year":"2013","journal-title":"Leukemia"},{"issue":"12","key":"2026022411375626400_bib87","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/bloodadvances.2022008990","article-title":"Zanubrutinib for the treatment of relapsed\/refractory hairy cell leukemia","volume":"7","author":"Tam","year":"2023","journal-title":"Blood Adv"},{"issue":"25","key":"2026022411375626400_bib88","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1182\/blood.2020009688","article-title":"Phase 2 study of ibrutinib in classic and variant hairy cell leukemia","volume":"137","author":"Rogers","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026022411375626400_bib89","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1158\/1535-7163.MCT-13-0639","article-title":"Picking the point of inhibition: a comparative review of PI3K\/AKT\/mTOR pathway inhibitors","volume":"13","author":"Dienstmann","year":"2014","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"2026022411375626400_bib90","doi-asserted-by":"crossref","first-page":"5618","DOI":"10.1158\/0008-5472.CAN-06-0364","article-title":"AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling","volume":"66","author":"Riemenschneider","year":"2006","journal-title":"Cancer Res"},{"issue":"41","key":"2026022411375626400_bib91","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"issue":"5","key":"2026022411375626400_bib92","doi-asserted-by":"crossref","first-page":"253","DOI":"10.5732\/cjc.013.10057","article-title":"Targeting the PI3K-AKT-mTOR signaling network in cancer","volume":"32","author":"Khan","year":"2013","journal-title":"Chin J Cancer"},{"issue":"7","key":"2026022411375626400_bib93","first-page":"715","article-title":"A review of PI3K inhibitors in B-cell malignancies","volume":"10","author":"Cannon","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"2026022411375626400_bib94","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/17474086.2019.1676716","article-title":"Therapeutic potential of PI3K signaling in distinct entities of B-cell lymphoma","volume":"12","author":"Wullenkord","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"2026022411375626400_bib95","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-12-86","article-title":"The complexity of NF-\u03baB signaling in inflammation and cancer","volume":"12","author":"Hoesel","year":"2013","journal-title":"Mol Cancer"},{"issue":"9","key":"2026022411375626400_bib96","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/2326-6066.CIR-14-0112","article-title":"NF-\u03baB, an active player in human cancers","volume":"2","author":"Xia","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2026022411375626400_bib97","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1600-065X.2011.01090.x","article-title":"NF-\u03baB subunit specificity in hemopoiesis","volume":"246","author":"Gerondakis","year":"2012","journal-title":"Immunol Rev"},{"issue":"1","key":"2026022411375626400_bib98","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: new insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"2026022411375626400_bib99","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00018-013-1545-4","article-title":"NF-\u03baB pathways in hematological malignancies","volume":"71","author":"Gasparini","year":"2014","journal-title":"Cell Mol Life Sci"},{"issue":"6916","key":"2026022411375626400_bib100","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/nature01148","article-title":"Rho GTPases in cell biology","volume":"420","author":"Etienne-Manneville","year":"2002","journal-title":"Nature"},{"key":"2026022411375626400_bib101","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/nrm2476","article-title":"Mammalian Rho GTPases: new insights into their functions from in vivo studies","volume":"9","author":"Heasman","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2026022411375626400_bib102","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1146\/annurev.cellbio.21.020604.150721","article-title":"Rho GTPases: biochemistry and biology","volume":"21","author":"Jaffe","year":"2005","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"3","key":"2026022411375626400_bib103","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1128\/MCB.17.3.1324","article-title":"Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways","volume":"17","author":"Westwick","year":"1997","journal-title":"Mol Cell Biol"},{"issue":"3-4","key":"2026022411375626400_bib104","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1155\/2010\/380291","article-title":"Rac GTPases in human diseases","volume":"29","author":"Pai","year":"2010","journal-title":"Dis Markers"},{"key":"2026022411375626400_bib105","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.4161\/cc.10.10.15612","article-title":"The diverse roles of Rac signaling in tumorigenesis","volume":"10","author":"Mack","year":"2011","journal-title":"Cell cycle"},{"issue":"2","key":"2026022411375626400_bib106","doi-asserted-by":"crossref","first-page":"745","DOI":"10.2353\/ajpath.2007.060557","article-title":"Central role of protein kinase C\u03b5 in constitutive activation of ERK1\/2 and Rac1 in the malignant cells of hairy cell leukemia","volume":"170","author":"Slupsky","year":"2007","journal-title":"Am J Pathol"},{"issue":"10","key":"2026022411375626400_bib107","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1158\/1535-7163.MCT-13-0164","article-title":"RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis","volume":"12","author":"Bid","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2026022411375626400_bib108","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/21541248.2016.1211398","article-title":"Rac1 in human diseases: the therapeutic potential of targeting Rac1 signaling regulatory mechanisms","volume":"8","author":"Marei","year":"2017","journal-title":"Small GTPases"},{"key":"2026022411375626400_bib109","doi-asserted-by":"crossref","first-page":"115180","DOI":"10.1016\/j.bcp.2022.115180","article-title":"Rac1 as a therapeutic anticancer target: promises and limitations","volume":"203","author":"Bailly","year":"2022","journal-title":"Biochem Pharmacol"},{"key":"2026022411375626400_bib110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1586\/ehm.10.16","article-title":"CXCL12 and CXCR4 in bone marrow physiology","volume":"3","author":"Moll","year":"2010","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"2026022411375626400_bib111","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.7150\/ijbs.82317","article-title":"CXCL12-CXCR4\/CXCR7 axis in cancer: from mechanisms to clinical applications","volume":"19","author":"Yang","year":"2023","journal-title":"Int J Biol Sci"},{"issue":"11","key":"2026022411375626400_bib112","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1002\/stem.1794","article-title":"SMAD signaling regulates CXCL12 expression in the bone marrow niche, affecting homing and mobilization of hematopoietic progenitors","volume":"32","author":"Khurana","year":"2014","journal-title":"Stem Cells"},{"issue":"4","key":"2026022411375626400_bib113","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.beha.2015.09.006","article-title":"The importance of the tissue microenvironment in hairy cell leukemia","volume":"28","author":"Sivina","year":"2015","journal-title":"Best Pract Res Clin Haematol"},{"key":"2026022411375626400_bib114","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/B978-0-12-411638-2.00002-1","article-title":"The intricate role of CXCR4 in cancer","volume":"124","author":"Chatterjee","year":"2014","journal-title":"Adv Cancer Res"},{"issue":"1","key":"2026022411375626400_bib115","doi-asserted-by":"crossref","first-page":"21252","DOI":"10.1038\/srep21252","article-title":"Potential role of AKT\/mTOR signalling proteins in hairy cell leukaemia: association with BRAF\/ERK activation and clinical outcome","volume":"6","author":"Lakiotaki","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"2026022411375626400_bib116","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41423-023-01110-0","article-title":"Glioma-derived ANXA1 suppresses the immune response to TLR3 ligands by promoting an anti-inflammatory tumor microenvironment","volume":"21","author":"Zheng","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"2026022411375626400_bib117","first-page":"PO.20.00518","article-title":"Hairy cell leukemia masquerading as CD5+ lymphoproliferative disease: the importance of BRAF V600E testing in diagnosis and treatment","volume":"5","author":"Soong","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"6","key":"2026022411375626400_bib118","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1007\/s11033-020-05509-0","article-title":"BRAF V600E mutation detection in hairy cell leukemia-utility of archival DNA from bone marrow aspirate\/imprint smear and amplification refractory mutation system","volume":"47","author":"Naseem","year":"2020","journal-title":"Mol Biol Rep"},{"issue":"1","key":"2026022411375626400_bib119","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1309\/AJCPDN4Q1JTFGCFC","article-title":"Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia","volume":"143","author":"Brown","year":"2015","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2026022411375626400_bib120","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1002\/1097-0142(19810415)47:8<2066::AID-CNCR2820470827>3.0.CO;2-V","article-title":"Splenectomy in hairy cell leukemia: a retrospective multicenter analysis","volume":"47","author":"Jansen","year":"1981","journal-title":"Cancer"},{"issue":"3","key":"2026022411375626400_bib121","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/1097-0142(19860201)57:3<644::AID-CNCR2820570341>3.0.CO;2-O","article-title":"Splenectomy for hairy cell leukemia: a clinical review of 63 patients","volume":"57","author":"van Norman","year":"1986","journal-title":"Cancer"},{"issue":"1","key":"2026022411375626400_bib122","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.mayocp.2011.09.001","article-title":"My treatment approach to hairy cell leukemia","volume":"87","author":"Naik","year":"2012","journal-title":"Mayo Clinic Proc"},{"issue":"6","key":"2026022411375626400_bib123","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1200\/JCO.1986.4.6.900","article-title":"Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients","volume":"4","author":"Golomb","year":"1986","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026022411375626400_bib124","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.V75.4.839.839","article-title":"Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a [see comments]","volume":"75","author":"Berman","year":"1990","journal-title":"Blood"},{"issue":"9","key":"2026022411375626400_bib125","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"issue":"2","key":"2026022411375626400_bib126","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JCO.1991.9.2.243","article-title":"Pentostatin induces durable remissions in hairy cell leukemia","volume":"9","author":"Cassileth","year":"1991","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026022411375626400_bib127","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1989.7.2.168","article-title":"Pentostatin in the treatment of advanced hairy cell leukemia","volume":"7","author":"Kraut","year":"1989","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026022411375626400_bib128","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"issue":"1","key":"2026022411375626400_bib129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.leu.2402784","article-title":"Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients","volume":"17","author":"Maloisel","year":"2003","journal-title":"Leukemia"},{"issue":"2 suppl 5","key":"2026022411375626400_bib130","first-page":"32","article-title":"Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study","volume":"27","author":"Johnston","year":"2000","journal-title":"Semin Oncol"},{"issue":"3","key":"2026022411375626400_bib131","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1200\/JCO.1997.15.3.1138","article-title":"Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up","volume":"15","author":"Hoffman","year":"1997","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026022411375626400_bib132","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1038\/sj.leu.2403418","article-title":"An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine","volume":"18","author":"Jehn","year":"2004","journal-title":"Leukemia"},{"issue":"5","key":"2026022411375626400_bib133","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/sj.leu.2400619","article-title":"Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey","volume":"11","author":"Lauria","year":"1997","journal-title":"Leukemia"},{"issue":"suppl 2","key":"2026022411375626400_bib134","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3109\/10428194.2011.570395","article-title":"Alternative methods of cladribine administration","volume":"52","author":"Lauria","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2026022411375626400_bib135","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.14129","article-title":"Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"issue":"16","key":"2026022411375626400_bib136","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","article-title":"Moxetumomab pasudotox: first global approval","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"2026022411375626400_bib137","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-01004-y","article-title":"Moxetumomab pasudotox in heavily pre-treated patients with relapsed\/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial","volume":"14","author":"Kreitman","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"25","key":"2026022411375626400_bib138","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/blood.2022016183","article-title":"Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy","volume":"140","author":"Handa","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2026022411375626400_bib139","doi-asserted-by":"crossref","first-page":"EVIDoa2300074","DOI":"10.1056\/EVIDoa2300074","article-title":"Vemurafenib and obinutuzumab as frontline therapy for hairy cell leukemia","volume":"2","author":"Park","year":"2023","journal-title":"NEJM Evid"},{"issue":"suppl 1","key":"2026022411375626400_bib140","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/hon.2594","article-title":"New treatment options in hairy cell leukemia with focus on BRAF inhibitors","volume":"37","author":"Falini","year":"2019","journal-title":"Hematol Oncol"},{"issue":"6","key":"2026022411375626400_bib141","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3324\/haematol.2022.281754","article-title":"Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience","volume":"108","author":"Chihara","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2026022411375626400_bib142","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.clml.2012.05.001","article-title":"Hairy cell leukemia: allogeneic transplantation could be an optimal option in selected patients","volume":"12","author":"Zinzani","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"2026022411375626400_bib143","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s11912-023-01419-z","article-title":"Hairy cell leukemia: where are we in 2023?","volume":"25","author":"Mendez-Hernandez","year":"2023","journal-title":"Curr Oncol Rep"},{"issue":"15","key":"2026022411375626400_bib144","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/blood.2021013502","article-title":"How I treat refractory\/relapsed hairy cell leukemia with BRAF inhibitors","volume":"139","author":"Falini","year":"2022","journal-title":"Blood"},{"issue":"149","key":"2026022411375626400_bib145","doi-asserted-by":"crossref","first-page":"ra84","DOI":"10.1126\/scisignal.2001148","article-title":"BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation","volume":"3","author":"Corcoran","year":"2010","journal-title":"Sci Signal"},{"issue":"4","key":"2026022411375626400_bib146","doi-asserted-by":"crossref","first-page":"336","DOI":"10.18632\/oncotarget.262","article-title":"Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers","volume":"2","author":"Corcoran","year":"2011","journal-title":"Oncotarget"},{"key":"2026022411375626400_bib147","doi-asserted-by":"crossref","first-page":"102137","DOI":"10.1016\/j.ctrv.2020.102137","article-title":"MEK inhibitor resistance mechanisms and recent developments in combination trials","volume":"92","author":"Kun","year":"2021","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"2026022411375626400_bib148","first-page":"665","article-title":"Drug resistance in targeted cancer therapies with RAF inhibitors","volume":"4","author":"Degirmenci","year":"2021","journal-title":"Cancer Drug Resist"},{"issue":"24","key":"2026022411375626400_bib149","doi-asserted-by":"crossref","first-page":"eabg0390","DOI":"10.1126\/sciadv.abg0390","article-title":"The stability of R-spine defines RAF inhibitor resistance: a comprehensive analysis of oncogenic BRAF mutants with in-frame insertion of \u03b1C-\u03b24 loop","volume":"7","author":"Yap","year":"2021","journal-title":"Sci Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1012\/2502867\/blooda_adv-2025-017165-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/4\/1012\/2502867\/blooda_adv-2025-017165-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T16:38:18Z","timestamp":1771951098000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/4\/1012\/548486\/Hairy-cell-leukemia-a-chronic-B-cell-lymphoma-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":149,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017165","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,24]]},"published":{"date-parts":[[2026,2,11]]}}}